CTOs on the Move

Colucid

www.colucid.com

 
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.colucid.com
  • P.O. Box 425227
    Cambridge, MA USA 02142
  • Phone: 781.365.2596

Executives

Name Title Contact Details

Funding

Colucid raised $55M on 05/07/2015

Similar Companies

Medical Laboratory Diagnostics

Find local doctors and healthcare providers near you. See their ratings, reviews, contact info, address, profile, and more.

Brains Bioceutical

Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API).

Medical Security Card Company

Medical Security Card Company is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Ancillare

Ancillary Supply Chain, Simplified Ancillare is the leader in end-to-end global clinical trial ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations. Ancillare is the first organization of its kind with an exclusive focus on the global clinical trial ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics, and regulatory experts. Ancillare`s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain. Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.